University of Texas at Austin: Dry powder inhalation could be a potent tool in COVID-19 antiviral treatment

University of Texas at Austin: Dry powder inhalation could be a potent tool in COVID-19 antiviral treatment. “The only antiviral drug currently used to treat SARS-CoV-2, the coronavirus that causes COVID-19, is remdesivir, but administering it is invasive and challenging. Scientists at The University of Texas at Austin are hoping to change that by using their novel thin-film-freezing technology to deliver remdesivir through dry powder inhalation, potentially making treatment more potent, easier to administer and more broadly available.”